Abstract
The prevalence of diabetes mellitus is increasing worldwide at an alarming rate due to population growth, obesity, sedentary lifestyle and aging. Consequently, diabetic microvascular complications (retinopathy and nephropathy) and macrovascular complications (coronary heart disease, peripheral arterial disease and cerebrovascular disease) are also rising. Traditional oral hypoglycaemic agents only partially prevent the development of these complications. This suggests that selective treatment options that target specific biological pathways (i.e. metabolic factors, intracellular signaling proteins and growth factors) may be a more effective strategy. Type 1 and Type 2 diabetic animal models have been produced spontaneously by selective inbreeding or by genetic modification, as well as, pharmacological induction. These models have become a safe and reliable option to test the therapeutic potential of novel drugs. They also help to understand the pathophysiology of diabetes mellitus. This review highlights the most commonly used animal models for the treatment of diabetic micro and macrovascular complications.
Keywords: Diabetes mellitus, animal models, microvascular complications, macrovascular complications
Current Pharmaceutical Design
Title: Animal Models of Diabetes Mellitus: Relevance to Vascular Complications
Volume: 14 Issue: 4
Author(s): Cecil S. Thompson
Affiliation:
Keywords: Diabetes mellitus, animal models, microvascular complications, macrovascular complications
Abstract: The prevalence of diabetes mellitus is increasing worldwide at an alarming rate due to population growth, obesity, sedentary lifestyle and aging. Consequently, diabetic microvascular complications (retinopathy and nephropathy) and macrovascular complications (coronary heart disease, peripheral arterial disease and cerebrovascular disease) are also rising. Traditional oral hypoglycaemic agents only partially prevent the development of these complications. This suggests that selective treatment options that target specific biological pathways (i.e. metabolic factors, intracellular signaling proteins and growth factors) may be a more effective strategy. Type 1 and Type 2 diabetic animal models have been produced spontaneously by selective inbreeding or by genetic modification, as well as, pharmacological induction. These models have become a safe and reliable option to test the therapeutic potential of novel drugs. They also help to understand the pathophysiology of diabetes mellitus. This review highlights the most commonly used animal models for the treatment of diabetic micro and macrovascular complications.
Export Options
About this article
Cite this article as:
Thompson S. Cecil, Animal Models of Diabetes Mellitus: Relevance to Vascular Complications, Current Pharmaceutical Design 2008; 14 (4) . https://dx.doi.org/10.2174/138161208783497679
DOI https://dx.doi.org/10.2174/138161208783497679 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Premature Ageing Prevention: Limitations and Perspectives of Pharmacological Interventions
Current Drug Targets Blood Pressure Variability/Dipper/Non-dipper in Hypertension and Diabetes
Current Hypertension Reviews Vitamins B1, B2, B3 and B9 – Occurrence, Biosynthesis Pathways and Functions in Human Nutrition
Mini-Reviews in Medicinal Chemistry Resveratrol as an Enhancer of Apoptosis in Cancer: A Mechanistic Review
Anti-Cancer Agents in Medicinal Chemistry The Predictive Value of Lipid Markers in Vascular Disease
Current Pharmaceutical Design The Etiology of Hypertension in the Metabolic Syndrome Part One: An Introduction to the History, the Concept and the Models
Current Vascular Pharmacology Human Anthrax as a Re-Emerging Disease
Recent Patents on Anti-Infective Drug Discovery ESVS Guidelines: Section A - Prevention in Patients with Carotid Stenosis
Current Vascular Pharmacology Hypoxia-Inducible Factor-1 in Arterial Disease: A Putative Therapeutic Target
Current Vascular Pharmacology An Updated Patent Therapeutic Agents Targeting MMPs
Recent Patents on Anti-Cancer Drug Discovery Embolic Protection Devices in Saphenous Vein Graft and Native Vessel Percutaneous Intervention: A Review
Current Cardiology Reviews Current Status of Computer-Aided Drug Design for Type 2 Diabetes
Current Computer-Aided Drug Design An Apple Plus a Brazil Nut a Day Keeps the Doctors Away: Antioxidant Capacity of Foods and their Health Benefits
Current Pharmaceutical Design Obesity and Body Composition in Man and Woman: Associated Diseases and the New Role of Gut Microbiota
Current Medicinal Chemistry Expression and Function of MicroRNAs in Heart Disease
Current Drug Targets Pharmacological Benefits of Active Components of Natural Products Against Traumatic Brain Injury - A Review
Current Pharmacogenomics and Personalized Medicine Evaluation of Fourteen Aurone Derivatives as Potential Anti-Cancer Agents
Current Pharmaceutical Biotechnology Lyn Regulates Cytotoxicity in Respiratory Epithelial Cells Challenged by Cigarette Smoke Extracts
Current Molecular Medicine Serum Microbial- and Host-Derived Markers of Periodontal Diseases: A Review
Current Medicinal Chemistry Cancer Prevention with Promising Natural Products: Mechanisms of Action and Molecular Targets
Anti-Cancer Agents in Medicinal Chemistry